Apple Inc.
November 1, 2021
1900-1930
November 1, 2021FDA clears RapidAI’s occlusion-spotting stroke software for CT scans
RapidAI has obtained FDA authorization for its artificial intelligence algorithms that instantly parse brain CT scans and spot suspected large vessel occlusions, leading to deadly or debilitating strokes.
The program was created to assist physicians in the triage of patients in a more effective way in a matter of minutes; this is done by tracking the blood vessels highlighted in the scan, which enables to assess areas of the brain with a reduced blood vessel density, which is a potential sign of a blood clot. This produces magnified angiography images with color-coded overlays from a typical CT scan.
The system also advises stroke team members when a large vessel occlusion is presumed. Furthermore, this June, RapidAI obtained a separate FDA computer-assisted diagnostic software authorization. The CADx category is a product meant to improve physicians’ descriptions of non-contrast CT scans.
RapidAI has obtained FDA authorization for its artificial intelligence algorithms that instantly parse brain CT scans and spot suspected large vessel occlusions, leading to deadly or debilitating strokes.
The program was created to assist physicians in the triage of patients in a more effective way in a matter of minutes; this is done by tracking the blood vessels highlighted in the scan, which enables to assess areas of the brain with a reduced blood vessel density, which is a potential sign of a blood clot. This produces magnified angiography images with color-coded overlays from a typical CT scan.
The system also advises stroke team members when a large vessel occlusion is presumed. Furthermore, this June, RapidAI obtained a separate FDA computer-assisted diagnostic software authorization. The CADx category is a product meant to improve physicians’ descriptions of non-contrast CT scans.
The automated program implements the standardized Alberta Stroke Program Early CT Scoring system, or ASPECTS, which is utilized to define the severity of a stroke and areas of irreversible brain damage. “Rapid ASPECTS outlines the next AI-powered step forward in stroke imaging, and the groundbreaking CADx authorization from the FDA puts it in a class by itself,” said RapidAI co-founder Greg Albers, a professor of neurology at Stanford University. “Besides helping stroke teams with more active triage and transfer arrangements, Rapid ASPECTS also improves.”
FDA Approves AI-Powered Automated Plate Assessment System
Innovations Limited and lab equipment inventor Hettich AG of Switzerland for the Automated Plate Assessment System (APAS). APAS proposes to automate and facilitate the process of examining microorganism cultures to conduct and expedite patient therapy.
The US FDA de novo permission was conferred following a successful one-year clinical trial where APAS matched and often surpassed the performance of qualified microbiologists in screening and reading agar plates correctly and efficiently. APAS operates by obtaining a digital image of an agar plate and then using artificial intelligence algorithms to understand and analyze any microorganism germination in fewer than 20 seconds.
Innovations Limited and lab equipment inventor Hettich AG of Switzerland for the Automated Plate Assessment System (APAS). APAS proposes to automate and facilitate the process of examining microorganism cultures to conduct and expedite patient therapy.
The US FDA de novo permission was conferred following a successful one-year clinical trial where APAS matched and often surpassed the performance of qualified microbiologists in screening and reading agar plates correctly and efficiently. APAS operates by obtaining a digital image of an agar plate and then using artificial intelligence algorithms to understand and analyze any microorganism germination in fewer than 20 seconds.
A qualified microbiologist typically needs one minute to accomplish this process. Based on these conclusions, some studies propose that APAS could cut processing values up to 40 percent. Furthermore, by decreasing the turnaround time upon receiving a specimen and reporting the outcomes to providers, APAS allows for quicker diagnosis and treatment classification for patients, providing better care quality
Given the estimation that 2.1 billion microorganism cultures are processed yearly, automated systems’ monetary, operational, and clinical weight become enormous. LBT Innovations and other medical development organizations, such as bioMérieux, continue fighting to expand the role of automation in microbiology workrooms.
A qualified microbiologist typically needs one minute to accomplish this process. Based on these conclusions, some studies propose that APAS could cut processing values up to 40 percent. Furthermore, by decreasing the turnaround time upon receiving a specimen and reporting the outcomes to providers, APAS allows for quicker diagnosis and treatment classification for patients, providing better care quality
Given the estimation that 2.1 billion microorganism cultures are processed yearly, automated systems’ monetary, operational, and clinical weight become enormous. LBT Innovations and other medical development organizations, such as bioMérieux, continue fighting to expand the role of automation in microbiology workrooms.